NeoHack Secures Two Patents for Formulations and Methods of Achieving Pain Relief
NeoHack: The Latest News
Press Release
December 15, 2025
NeoHack Life Sciences Seeks Licensees for its Patented “Synergistic Combinations” that Reset the Body’s Set Point (Homeostasis), including for Alzheimer’s and Other Disease States.
FOR IMMEDIATE RELEASE
Scottsdale, AZ – December 15, 2025 – NeoHack Life Sciences, a leader in the development of naturals and nature-identical components to control inflammation and pain, today announced that it is actively seeking licensees for its patented “Compositions and Methods of Achieving Pain Relief”.
The technology, which has demonstrated the ability to reverse multiple chronic inflammatory responses ranging from joint pain and shingles to high blood pressure, Crohn’s disease and even Alzheimer’s, represents a significant opportunity for companies looking to target the maladies afflicting the growing “baby boomer” population.
The patents cover a “Synergistic Combination” that crosses the Blood Brain Barrier (BBB) and lends itself to topical and other applications.
Key Features of NeoHack’s Work:
NeoHack’s “Components and Methods” work focuses on achieving positive therapeutic effects via targeting specific pathways including the Central Nervous System. The components are quickly absorbed, metabolized, and excreted resulting in fast pain relief, inflammation reduction, and restoration of homeostasis without damaging the body. The pharmacological impact exhibited by these specific compounds includes actions such as central nervous system stimulation and simultaneously reducing amyloid plaques in the brain.
About the Proprietary Product’s Patents (US12,370,156 and US12,303,476)
1. All of the components of the patented “Synergistic Combination” enhance NRF2, acritical pathway which is the body’s master regulator of homeostasis and cellular defense against oxidative stress and toxins, working by activating protective genes.
2. All of our components reduce MCP-1. (Monocyte Chemoattractant Protein-1), also known as CCL2, a crucial small protein (cytokine) that acts as a chemical signal to attract immune cells, especially monocytes and macrophages, to sites of inflammation, infection, or injury. These steps play a vital role in immune responses and various diseases like atherosclerosis, kidney disease, and neurological disorders by directing immune cell traffic and promoting inflammation. (https://pmc.ncbi.nlm.nih.gov/articles/PMC8135227/)
3. All of our components effectively address a porous blood-brain barrier (BBB), meaning the barrier is leaky, losing its tight seal and allowing unwanted substances (toxins, immune cells) into the brain, disrupting nutrient flow, and impairing waste removal, often seen in diseases like Alzheimer’s or stroke, contrasting with its normal role as a protective, selective filter. (https://pubmed.ncbi.nlm.nih.gov/24009582/)
4. All of our components can play a role in Tau Tangles research. The defining features of Alzheimer disease (AD) include conspicuous changes in both brain histology and behavior. The AD brain is characterized microscopically by the combined presence of 2 classes of abnormal structures, extracellular amyloid plaques and intraneuronal neurofibrillary tangles, both of which comprise highly insoluble, densely packed filaments. The soluble building blocks of these structures are amyloid-β (Aβ) peptides for plaques and tau tangles.
(https://pubmed.ncbi.nlm.nih.gov/24493463/)
A Strategic Opportunity:
“We believe this patented technology has the power to redefine healthcare, preferably with a partner poised to fully unlock its potential. This is a unique chance for a licensee to gain a strategic advantage in addressing the challenges of an aging population,” said NeoHack CEO, Ron Butler. We welcome inquiries about an IP licensing agreement.
Next Steps for Interested Parties:
Interested strategic parties are encouraged to contact senior management:
CEO Ron Butler (rb@neohacksciences.comand
Chief Science Officer, Dr. Dale Brown (db@neohacksciences.com)
_________________________________________________________________________________
December 2, 2025: Alzheimer’s disease projected to surge with 100 million new cases by 2050:
NeoHack is working to stop that from happening
“Alzheimer’s disease (AD) is a destructive neurodegenerative disease that is characterized by progressive cognitive impairment and poses a severe threat to the life and health of patients” (Tang et al., 2017; Hayashi et al., 2020; Huang et al., 2021; Terreros-Roncal et al., 2021).
In 2024, the Food and Drug Administration (FDA) published guidance on Alzheimer’s disease as an “irreversible, progressive brain disorder affecting more than 6.5 million Americans. While the specific causes of Alzheimer’s are not fully known, it is characterized by changes in the brain—including the formation of amyloid beta plaques and neurofibrillary, or tau, tangles—that result in loss of neurons and their connections.” (FDA publication notice Content current as of: 03/11/2024).
At NeoHack Life Sciences, our 2025 patents cover formulation components that address the root causes of Alzheimer’s.
Ingredient C causes stem cells to multiply. Why is this critical?
The body’s own Neural Stem Cells (NSCs) are a potential target because they can replace lost neurons and promote repairs.
Ingredient P enhances Brain Derived Neurotrophic Factor (BDNF) and preserves its production. Why is this important?
Preventing the loss BDNF is critical if AD is to be stopped early, and even prevented.
Ingredient D can activate the BDNF pathway. Why is this important?
It has shown neuroprotective effects such as mitigating neurotoxicity are essential.
Ingredient M can increase BDNF levels. Why is this important?
This is a complex relationship and depends on context showing that it may alleviate neuroinflammation.
Collectively, these ingredients help reduce inflammation and allow the body’s stem cells to replace damaged neurons by crossing the Blood Brain Barrier (BBB).
Why is this important?
From the Cleveland Clinic: “The blood-brain barrier (BBB) protects the brain by filtering harmful substances from the blood, while still allowing essential nutrients in. Its main functions include protection, nutrient supply, waste removal, and brain homeostasis. It is composed of several cellular components that work together to tightly regulate what enters and leaves the brain's central nervous system” ₁
Brains can shrink when not in homeostasis, the body’s set point, so restoration is important to start the repair process early, in order to address amyloid plaques and tau tangles. The linked study from Stanford University addresses these issues. Rethinking Alzheimer's: Untangling the sticky truth about tau
₁https://my.clevelandclinic.org/health/body/24931-blood-brain-barrier-bbb
November 21, 2025: Alzheimer’s Disease has recently been addressed by NeoHack Life Sciences LLC.
After many years of FDA licensed manufacturing of oral care ingredients, products and devices for global brands and retailers, the principals of predecessor WhiteHill, discovered user outcomes in healing beyond periodontal disease and Xerostomia. Its delivery systems included lozenges, sprays, rinses and dermal applications.
Concerted R & D started in 2017 focusing on the experiences reported by users of the oral care items and then our 2025 patent work. Those results included healing herpes simplex virus type 1 (HSV-1), irritable bowel syndrome (IBS), and related conditions.
The patents explain the life changing results as seen in this link: https://neohacksciences.com/newest-patents
Methods and formulations are listed in those patents which are identified in US 12,370,156 published on July 29, 2025 and linked above.
The cumulative market for these diseases, disorders and medical maladies is approaching $2.0 trillion.
Our patent research focused on resetting inflammation to the body’s “set point”, known as homeostasis. The role of NRF2 (nuclear factor erythroid 2-related factor 2) a protein that acts as a master regulator of homeostasis, the cell's protective response against stress, particularly oxidative and inflammatory stress.
Our delivery methods include lozenges, sprays, rinses, gummies, oral doses, and dermal applications. The patent uses formulations to control proper level of NRF2.
We appreciate the review of 212 references compiled by Ching-Tung Chu et al on the publication of Role of NRF2 in Pathogenesis of Alzheimer's Disease (PMID: 39765857 PMCID: PMC11727090).
The following is a statement from the paper, with which we concur:
“NRF2 has been reported to modulate microglia-induced inflammation and facilitate the transition from homeostatic microglia to a disease-associated microglia subset. Genetic and pharmacological activation of NRF2 has been demonstrated to improve cognitive function. Here, we review the current understanding of the involvement of NRF2 in AD and the critical role that NRF2 plays in microglia in the context of AD. Our aim is to highlight the potential of targeting NRF2 in the microglia as a promising therapeutic strategy for mitigating the progression of AD.”
Our patent addresses modulation of NRF2 in claim 5. The patent is even more exciting in light of the Ching-Tung Chu et al.
November 17, 2025
ITCH (pruritus)…
something to not scratch off your list of things that irritate you
Itching can be a signal that your body is dealing not just with skin irritation (cutaneous), but perhaps with nerve damage (neuropathic), a central nervous system problem (neurogenic), or even a stress response (psychogenic).
The global pruritus (itching) market is substantial and expected to grow, driven by the rising prevalence of related conditions like atopic dermatitis. The market is projected to reach approximately $8.93 billion in 2024 and grow to around $11.34 billion by 2030, at a compound annual growth rate (CAGR) of about 4.1%.
Key factors fueling growth include increasing investment in research and development, a growing geriatric population, and the introduction of new and innovative therapies from entities like NeoHack Life Sciences, although challenges like regulatory hurdles and high therapy costs exist. (https://pmc.ncbi.nlm.nih.gov/articles/PMC10391209/).
Whether associated with injuries, disease treatments, or often enough no readily identifiable cause, pruritus or itching can become a chronic detriment to health and healing.
Our groundbreaking patents (https://neohacksciences.com/newest-patents) introduce key herbal components used in food flavoring already tested and deemed safe. Importantly, these components we use are not cost prohibitive.
Our methods and formulations address, (1) cutaneous (skin inflammation or irritation), (2) psychogenic (perhaps mental issues at work), (3) neuropathic (nerve damage), and (4) neurogenic (central nervous system) itch.
By addressing Tumor Necrosis Factor alpha, (TNF-α), cutaneous, neurogenic, and neuropathic itch can be controlled. While there is no direct link to psychogenic itch, stress can lead to elevated levels of TNF-α, which indirectly controls itch.
For more information on our recent patents please contact NeoHack Life Sciences LLC:
Chief Science Officer, Dr. Dale G. Brown, PhD db@neohacksciences.com
CEO, Ron Butler at rb@neohacksciences.com.
October 28, 2025
Dementia markers in the brain and living environment influences
Researchers at Wake Forest University School of Medicine have produced an amazing piece of work recently published with the title, Associations of place-based social determinants of health with biomarkers of Alzheimer's disease and related dementias.[1] The link to the publication is included here. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/bsa3.70030
The INTRODUCTION identifies social determinants of health (SDoH) defined as “where people live, work, play and age” and “the overlapping effects of race and place on health have been studied extensively”.
We have posted blogs on our website, https://neohacksciences.com/, making the connection between chronic inflammation and neurodegenerative disorders dealt within our most recent patents issued published in May and July 2025 by the USPTO. https://neohacksciences.com/newest-patents.
We believe that any insult to the brain results in an inflammatory response.
Chronic inflammation is a prolonged state of inflammation that can last for weeks, months, or even years. Addressing inflammation is essential for treating many disorders.
The May patent contains 20 claims for methods of treating pain and resulting conditions for certain disorders including Alzheimer’s Disease. The July patent covers formulations for the same disorders.
We believe by using components deemed safe for inclusion in the food chain and methods easily produced, a treatment can be widely distributed at affordable prices and can have a huge positive impact on place-based SDoH.
Footnotes:
1Krishnamurthy, S., et al. (2025) Associations of place-based social determinants
of health with biomarkers of Alzheimer's disease and related dementias.
Alzheimer's & Dementia: Behavior & Socioeconomics of Aging.
Full Disclosure: Our CEO Ron Butler earned the MBA degree from the Wake Forest School of Business and served for 20 years on its Board of Visitors but has no association with its School of Medicine or any of the named authors.
The Brain and Neuroinflammation
"Everything we do, every thought we've ever had, is produced by the human brain. But exactly how it operates remains one of the biggest unsolved mysteries, and it seems the more we probe its secrets, the more surprises we find" — BrainyQuote Neil deGrasse Tyson
The brain is amazing in terms of what it does and can do to help our bodies remain in the healthy set point called homeostasis. Unfortunately, the brain can be subjected to injury, infection, disease, or excessive inflammation.
One study from 2018 indicated that out of 22.6 million patients with neurological disorders, 13.8 million required surgery, according to Centers for Neurosurgery Spine & Orthopedics.
Neuroinflammation is an immune response within the central nervous system (CNS), triggered by injury, infection, or disease, involving activated immune cells like microglia and astrocytes and can be a beneficial response to protect the brain. However, if it persists it can lead to chronic low-grade irritation.
Neuroinflammation can be a beneficial response to protect the brain by helping remove pathogens and clear damaged cells and debris thus protecting the healthy set point of homeostasis.
If the inflammation persists or is not adequately controlled, it can lead to chronic, low-grade irritation, resulting in ongoing damage to brain tissue and neurodegeneration.
Neuroinflammation can damage the blood-brain barrier (BBB), potentially allowing peripheral immune cells to enter the CNS and exacerbate the inflammation.
Neurotoxicity can result in free radicals and other inflammatory byproducts that can damage neurons and other CNS cells.
While initially a protective mechanism to clear debris and fight pathogens, chronic or uncontrolled neuroinflammation can cause damage, leading to neurodegeneration and contributing to diseases such as Alzheimer's and Parkinson's disease.
Our most recent patents are instrumental in stopping excessive neuroinflammation.
See our patents section via this link https://neohacksciences.com/newest-patents
NeoHack's journey to pain relief, reversing inflammation and restoring homeostasis actually began in oral health. An early research team, focused solely on developing a dry mouth product, stumbled upon the nickname of a key ingredient -- “the toothache plant” -- and the rest is history.
NeoHack is now devoted to understanding how five natural and nature-identical substances, including the "toothache plant" reverse multiple associated chronic inflammatory responses. Read on to review NeoHack's first case study.
NeoHack's First Case Study on Pain
DAY ONE: Patient Suffers from Painful Rheumatoid Arthritis
Patient 1 presented with extremely painful, swollen hands. Chief complaint was the inability to bend the fingers and grip things, including the steering wheel. The patient began applying the natural compound -- known for centuries as a pain reliever --in lotion form, 3 times daily.
DAY FOUR: Patient Reports Significant Improvement
Patient 1 reported significant reduction in swelling and pain as early as DAY FOUR. Patient continued application of the natural compound in lotion form, 3 times daily.
DAY SEVEN: Patient Reports Pain and Swelling Resolved
The unexpected resolution of chronic pain and swelling in JUST SEVEN DAYS became the cornerstone of another half-decade of research, dozens more NeoHack case studies and a recent patent.
Cookie Policy
This website uses cookies. By continuing to use this site, you accept our use of cookies.